文献速递肝病

非酒精性脂肪性肝病瘦型患者代谢合并症较少但死亡率更高

Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.
PubMed 文献 · Aliment Pharmacol Ther · 2023-02-23

该单中心回顾性研究纳入2012至2021年非酒精性脂肪性肝病成人,比较瘦型与非瘦型患者的死亡及肝硬化、心血管疾病、糖尿病和癌症发生率。瘦型患者基线代谢病患病率及肝硬化、糖尿病发生率更低,但死亡率显著更高(每1000人年16.67 vs 10.11、7.37、8.99)。

要点

  • 瘦型非酒精性脂肪性肝病患者死亡率高于超重及肥胖患者。
  • 瘦型患者肝硬化及糖尿病发生率低于非瘦型患者。
  • 瘦型与非瘦型患者心血管疾病及癌症发生率无差异。

核心结论

  • 瘦型非酒精性脂肪性肝病患者尽管肝硬化及糖尿病发生率更低、心血管疾病及癌症发生率相似,但死亡率更高,应给予与非瘦型患者相似甚至更多关注。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2021年非酒精性脂肪性肝病成人,横断面分析18594例,纵向分析13420例。

主要发现

  • 瘦型约占11%,超重约25%,1级肥胖约28%,2-3级肥胖约35%;中位年龄51.0岁,女性占54.6%,中位随访49.3个月。
  • 瘦型患者基线代谢病患病率及随访期间肝硬化、糖尿病发生率低于非瘦型患者。
  • 随访期间瘦型与非瘦型患者心血管疾病、任何癌症或肥胖相关癌症发生率无差异。
  • 每1000人年死亡率在瘦型、超重、1级肥胖、2-3级肥胖组分别为16.67、10.11、7.37、8.99,瘦型组显著更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) can develop in individuals who are not overweight. Whether lean persons with NAFLD have lower mortality and lower incidence of cirrhosis, cardiovascular diseases (CVD), diabetes mellitus (DM) and cancer than overweight/obese persons with NAFLD remains inconclusive. We compared mortality and incidence of cirrhosis, CVD, DM and cancer between lean versus non-lean persons with NAFLD. METHODS: This is a retrospective study of adults with NAFLD in a single centre from 2012 to 2021. Primary outcomes were mortality and new diagnosis of cirrhosis, CVD, DM and cancer. Outcomes were modelled using competing risk analysis and Cox proportional hazards regression analysis. RESULTS: A total of 18,594 and 13,420 patients were identified for cross-sectional and longitudinal analysis respectively: approximately 11% lean, 25% overweight, 28% class 1 obesity and 35% class 2-3 obesity. The median age was 51.0 years, 54.6% were women. The median follow-up was 49.3 months. Lean patients had lower prevalence of metabolic diseases at baseline and lower incidence of cirrhosis and DM than non-lean patients and no difference in CVD, any cancer or obesity-related cancer during follow-up. However, lean patients had significantly higher mortality with incidence per 1000 person-years of 16.67, 10.11, 7.37 and 8.99, respectively, in lean, overweight, obesity class 1 and obesity class 2-3 groups respectively. CONCLUSIONS: Lean patients with NAFLD had higher mortality despite lower incidence of cirrhosis and DM, and similar incidence of CVD and cancer and merit similar if not more attention as non-lean patients with NAFLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023. PMID: 36815445. doi:10.1111/apt.17424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。